about
Drug interactions and immunosuppression in organ transplant recipientsIndividualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejectionAre octogenarians with end stage renal disease candidates for renal transplantation?Exposure to Mycophenolate and Fatherhood.Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients.Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation.The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.Benefit of kidney transplantation beyond 70 years of ageMore potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.Management strategies for posttransplant hypertension.Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipientsEndothelial dysfunction is associated with graft loss in renal transplant recipients.Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingThe impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation.One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allograftsImproved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study.Use of Neoral C monitoring: a European consensus.Should patients older than 65 years be offered a second kidney transplant?Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients.Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot studyInclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.Importance of hematocrit for a tacrolimus target concentration strategy.Renal transplantation is also an option for patients over 70.A drug safety evaluation of everolimus in kidney transplantation.European perspective on human polyomavirus infection, replication and disease in solid organ transplantation.How to Report and Interpret Bioequivalence Data in Solid Organ Transplant Recipients.Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants.Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients.The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.Prediction of Fat-Free Mass in Kidney Transplant Recipients.Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.Changes in health related quality of life in older candidates waiting for kidney transplantation.NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation.Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation.High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation.Successful treatment of spontaneous kidney graft decapsulation 18 years after renal transplantation: a case report.Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations.Induction with interleukin-2 antagonist for transplantation of kidneys from older deceased donors: an observational study.Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
P50
Q27013722-AE2D49C1-27E1-4B45-8F64-51738D288272Q28209762-A09A0B16-50C1-4519-86A8-F5847002AD83Q30489630-ED946E48-E6D4-45E1-9B08-7230434778D8Q30491234-29765FE3-6607-47DF-9E7D-DEB25B7AA7FEQ30683373-2718A893-198B-4CCB-9D76-A23BB50FED33Q33369997-98D2CB11-4B12-4FDA-96FD-EAF72B71B703Q33408297-DE47F4BA-E0AE-4175-B0E5-7B7C31947003Q33628473-B3C195EB-7FDE-49EF-BEE9-F767E390C6E2Q33797543-D7201E63-5D9A-4F08-B1C3-7EB4B4D353BAQ34023028-34F5F27C-7CB3-4F34-B16A-8B7D6CA63209Q34127620-B83D9EF9-1CFD-4782-AA83-1756A08BF61EQ34556614-52C8D442-9599-477D-BBB0-A52A3BAA434DQ34567870-99352625-3C2D-4104-9686-A29F1397A85DQ34571036-2C4C5666-9207-4808-B425-8234E847F6D3Q35001130-E7AD481F-F244-4651-B31A-858C726576B9Q35565364-68704673-1541-4521-813C-2560A0829658Q36113092-1BD31A3D-F052-43AD-8CB3-E4A93C44CA4EQ36158864-2CBEF480-809E-4482-AF66-30DC3A344A25Q36246612-6E50C97A-2501-439E-BC25-47D9FB5FC316Q36578296-F8486785-6FF0-4B57-A7E0-FE727B6C8ACEQ37299171-6235824E-E49F-4E10-908F-473EF22BD821Q37366663-4D54A0FD-5EB7-4A81-8CB5-DAB7102B6AA6Q37469289-BC4DCE87-83F9-4D21-B64A-8903CB64065BQ37948003-68D58024-AD9A-4D1E-9BDE-327E943DDB06Q38041260-C88DE408-69F2-4A86-9BCD-9C20E7572C30Q38183118-7F2B3C3F-077C-436E-9336-B8968BB467B3Q38634745-3330607F-F547-43B2-8FF7-A0F0DCBDF3AEQ38699017-D942F654-54D0-47C9-8E94-3071278FC878Q38957499-6936133A-F6EA-4FC9-A13E-AD2C44765EE0Q38986439-88FC27E0-2F44-4BCC-A91D-679DA1B8652CQ39885653-DE410407-5B21-4870-AFC9-28F2EFEE3AB7Q40015538-C943F02B-3347-4792-A242-B33DFCA06E3CQ40112534-128E8307-2C9A-48B7-9447-22A39C265E45Q40131984-A7A121E4-A1BD-44B1-8E8A-E225BF03A316Q40162549-AB7F1F8D-C430-45D1-91DA-4249973621B9Q40223570-A6C34C03-252B-49DC-97C5-A7CA8F150D48Q40333404-90625973-396C-4ABD-B22D-CBBC063E2E5DQ41614362-BB57E191-321D-4E63-BBDE-B9987E57F04BQ42157160-7EF07017-E049-4EFA-8F05-462BEA1DC088Q42661818-DE0854B9-5D6E-478D-A6C7-46D7215A95D0
P50
description
Noors arts
@nl
norsk overlege
@nb
researcher
@en
name
Karsten Midtvedt
@en
Karsten Midtvedt
@nb
Karsten Midtvedt
@nl
type
label
Karsten Midtvedt
@en
Karsten Midtvedt
@nb
Karsten Midtvedt
@nl
prefLabel
Karsten Midtvedt
@en
Karsten Midtvedt
@nb
Karsten Midtvedt
@nl
P106
P2038
Karsten_Midtvedt
P21
P214
27149296261980670008
P2287
P27
P31
P496
0000-0002-3302-1110
P6634
karsten-midtvedt-2224a830